ADITUM
Enrich your Research

Oncology and Cancer Screening

Research Article

A Review of Novel Therapeutics and Precision Medicine for Cervical Malignancies

Kshama Deshmukh[1], Saket Kumar Deshmukh[2], Naryan Dixit[3], Khushi Sahu[4], Deepika Mandavi[5], Hari Prasad Sonwani[*]

Apollo College of Pharmacy, Durg 491001(Chhattisgarh), India.

Article Info

Received: April 15, 2026
Accepted: May 03, 2026
Published: May 12, 2026

***Corresponding author:** Hari Prasad Sonwani, Apollo College of Pharmacy, Durg 491001(Chhattisgarh), India.

Citation: Deshmukh K, Saket K Deshmukh, Dixit N, Sahu K, Mandavi D, Hari P Sonwani. (2026) "A Review of Novel Therapeutics and Precision Medicine for Cervical Malignancies", Oncology and Cancer Screening, 7(1); DOI: 10.61148/2994-8746/JOCS/071

Copyright: © 2026 Hari Prasad Sonwani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract:

Background: Cervical cancer continues to be a leading cause of oncological mortality among women globally, particularly in low-resource settings. While conventional therapies—surgery, radiotherapy, and cisplatin-based chemotherapy—remain the standard of care, outcomes for advanced, recurrent, or metastatic disease remain poor. Objective: This review synthesizes recent clinical advancements (2020–2025) and evaluates the shifting therapeutic landscape toward precision medicine and immunotherapy. Methods: A comprehensive literature review was conducted focusing on Phase II/III clinical trials involving immune checkpoint inhibitors (ICIs), targeted agents, and novel delivery systems. Results: Recent data, including the KEYNOTE-A18 and GOG-3047 trials, have redefined the standard of care by integrating pembrolizumab with concurrent chemoradiation for locally advanced disease. Furthermore, the emergence of Antibody-Drug Conjugates (ADCs) like tisotumab vedotin and novel HER2-directed therapies offers new hope for refractory cases. Advances in gene editing (CRISPR/Cas9) and oncolytic virotherapy (targeting E6/E7 oncoproteins) are showing promise in early-phase translational research. Conclusion: The integration of immunotherapy into first-line protocols represents a paradigm shift in cervical cancer management. Future efforts must focus on identifying predictive biomarkers and overcoming the immunosuppressive tumor microenvironment to further reduce the global disease burden.

Keywords: HPV, Chemotherapy, Immunotherapy, Targeted therapy

Introduction:

A Shifting Paradigm in Cervical Cancer

Cervical cancer remains a significant and formidable global health concern, ranking as the fourth most common malignancy affecting women worldwide and accounting for approximately 340,000 to 350,000 deaths annually.[1] Despite advancements in screening, the disease burden remains disproportionately high in low- and middle-income countries. The primary and most well-established etiology for cervical cancer is persistent infection with High-Risk Human Papillomavirus (HPV). Extensive molecular research indicates that frequent and chronic HPV infection is responsible for virtually 99.7% of all cervical cancer cases,[2] primarily driven by the oncogenic proteins E6 and E7 which disrupt host cell-cycle regulation.

Furthermore, a critical intersection exists between viral pathogens; there is substantial proof that women infected with the Human Immunodeficiency Virus (HIV) are at a significantly higher risk of acquiring persistent HPV. The immunocompromised state induced by HIV impairs the body's ability to clear viral infections, leading to a drastically accelerated risk of malignant transformation.[3] Current clinical data suggests that women living with HIV face a six-fold greater risk of developing invasive cervical cancer compared to their HIV-negative counterparts.[3]

Effective clinical management necessitates accurate staging prior to the initiation of any therapeutic intervention. This is traditionally conducted using the International Federation of Gynecology and Obstetrics (FIGO) system, which categorizes the disease from Stage I through Stage IV.[4] This classification is a vital prognostic tool, determined by a multidisciplinary assessment of tumor size, depth of stromal invasion, and the anatomical extent of metastatic spread to adjacent organs or distant sites.[4]

The therapeutic approach is highly stage-dependent. Initial or early-stage disease is typically managed through definitive surgical resection, such as radical hysterectomy, or primary radiotherapy. Conversely, advanced-stage malignancies require a more intensive multimodal strategy, usually involving a combination of pelvic external beam radiotherapy and cisplatin-based chemotherapy.[5] While these traditional "backbone" therapies can be curative if the spread is localized, they often carry a high risk of long-term morbidity and systemic toxicity.

Over the past decade, and particularly moving into 2025, there has been a significant and rapid development in the pharmacological landscape of cervical cancer. The emergence of targeted biologics, immunotherapy, and antibody-drug conjugates (ADCs) has begun to redefine the standard of care, offering improved patient survival rates and significantly enhanced safety profiles. This review aims to provide a comprehensive and updated overview of the pharmacological agents currently available and those on the horizon for the management of cervical cancer.

Cervical Cancer Disease Management

Cervical cancer disease management typically involves a **multidisciplinary approach** tailored to the individual patient's needs and the stage of the disease. In the modern therapeutic landscape (2024–2025), this approach has shifted from a rigid "one-size-fits-all" model to **precision-based oncology**, prioritizing both oncological clearance and the patient's quality of life.

Key components of cervical cancer management include:

Multidisciplinary Team (MDT) Consultation

The complexity of cervical cancer requires the collaborative expertise of a diverse medical team. A standard MDT for cervical cancer includes:

- **Gynecologic Oncologists:** Specialized surgeons who lead the surgical management and often oversee the integration of chemotherapy.
- **Radiation Oncologists:** Experts in utilizing external beam radiation (EBRT) and brachytherapy, which remain the "gold standard" for locally advanced disease.
- **Radiologists and Pathologists:** Responsible for high-fidelity staging using MRI, PET-CT, and molecular testing (such as HPV typing and PD-L1 expression levels).
- **Supportive Care Specialists:** Including oncology nurses, psycho-oncologists, and fertility specialists who address the psychosocial and reproductive implications of the diagnosis.[2]

2. Precision Staging and Imaging

Management cannot begin without precise staging according to the **FIGO (2018/updated)** guidelines.

- **Modern Imaging:** While clinical examination was traditionally the primary tool, **Pelvic MRI** is now the preferred modality for assessing tumor size and local invasion, while **FDG PET-CT** is critical for detecting lymph node involvement and distant metastases.
- **AI-Assisted Staging:** In 2025, deep learning models (such as HRNet) are increasingly used to assist radiologists in identifying subtle stromal invasion and parametrial spread, ensuring more accurate treatment stratification.

3. Surgical Intervention and Fertility Preservation

For early-stage disease (Stage IA to IB1), surgery is often the primary treatment:

- **Radical Hysterectomy:** The removal of the uterus, cervix, and surrounding parametrial tissue.
- **Fertility-Sparing Surgery (FSS):** For patients of reproductive age with small tumors (<2 cm), options like **Radical Trachelectomy** (removing the cervix but sparing the uterine fundus) allow for the possibility of future pregnancy.
- **Sentinel Lymph Node (SLN) Mapping:** A less invasive technique to identify the first draining lymph nodes, reducing the need for full pelvic lymphadenectomy and decreasing the risk of lymphedema.

4. Chemoradiotherapy (The "Backbone" of Advanced Care)

For locally advanced stages (Stage IIB to IVA), the standard of care is **Concurrent Chemoradiotherapy (CCRT)**:

- **Cisplatin-Based Chemotherapy:** Acts as a radiosensitizer to enhance the efficacy of radiation.
- **Image-Guided Brachytherapy (IGBT):** Allows for the delivery of high-dose radiation directly to the tumor while sparing healthy bladder and rectal tissue, significantly improving local control rates.

5. Novel Pharmacological and Systemic Therapies

The most significant evolution in management involves systemic treatments for recurrent or metastatic disease:

- **Immunotherapy:** The addition of **Pembrolizumab** to standard chemoradiation has shown a significant survival benefit in recent landmark trials (e.g., KEYNOTE-A18).
- **Antibody-Drug Conjugates (ADCs):** Targeted agents like **Tisotumab vedotin** are now used for patients who have progressed after first-line chemotherapy, offering a "trojan horse"

Copy right © Hari Prasad Sonwani

approach to deliver toxins directly to cancer cells.

6. Palliative Care and Survivorship

- Management extends beyond active treatment to include **long-term surveillance** and palliative support. This involves monitoring for recurrence through regular cytological and imaging follow-ups, as well as managing treatment-related side effects such as sexual dysfunction, vaginal stenosis, and chronic pelvic pain. [6]

Supportive Care and Integrated Disease Management

Throughout the entire disease management process, **comprehensive supportive care** measures are integral to addressing the multifaceted physical, emotional, and social needs of patients. This holistic approach extends beyond tumor eradication to include proactive pain management, nutritional optimization, specialized psychological counseling, and facilitated access to community-based resources.[6,7]

Modern protocols emphasize an **integrated and patient-centered model**, which aims to achieve optimal oncological outcomes while aggressively minimizing treatment-related toxicities and preserving the patient's long-term quality of life. Achieving this balance requires seamless **multidisciplinary collaboration** among gynecologists, medical oncologists, radiation oncologists, and supportive care specialists. Such coordination ensures that patients receive "total care" that addresses both the malignancy and the person living with it.

Systemic Therapy and Standard of Care

The contemporary standard for the majority of cervical cancers remains **systemic platinum-based chemotherapy** administered concurrently with radiotherapy. This synergistic combination has consistently demonstrated superior clinical outcomes—specifically in terms of **disease-free survival (DFS)** and **overall survival (OS)**—when compared to radiotherapy as a monotherapy. While concomitant chemoradiotherapy is highly effective, it is associated with an increased risk of systemic toxicity, including:

- **Hematological stress:** Such as leukopenia and anemia.
- **Gastrointestinal distress:** Including nausea and radiation-induced enteritis.

However, these side effects are generally manageable through modern supportive interventions. The selection of **adjuvant therapy** is meticulously tailored based on the individual risk of relapse, with "high-risk" patients—defined by factors like positive lymph nodes or parametrial involvement—requiring intensive chemoradiotherapy to mitigate recurrence.[8]

Advances in Refractory and Stage IVB Disease

Numerous landmark studies have solidified the role of platinum agents in improving the **overall survival rate**, reinforcing their status as the foundation of treatment for nearly all cervical cancer patients.[9-12] Despite this, managing recurrent or metastatic disease remains a significant clinical challenge.

A transformative advancement in this space was highlighted by **Tewari KS et al.**, who demonstrated that **cemiplimab**—a PD-1 checkpoint inhibitor—significantly improved survival outcomes compared to traditional single-agent chemotherapy in patients whose disease recurred following first-line platinum therapy.[13]Key findings from this study included:

- **Objective Response Rate (ORR):** 16.4% in the cemiplimab group versus only 6.3% in the chemotherapy cohort.
- **Clinical Significance:** This represents a major breakthrough for a patient population that previously had very limited therapeutic options.

For patients diagnosed with **Stage IVB cervical cancer**, the management strategy is distinct. Unlike locally advanced cases, Stage IVB does not have a singular, universally defined standard of care. For those who are ineligible for extensive surgery or radical radiation, systemic chemotherapy remains the primary tool. While traditional cytotoxic drugs were often ineffective at completely eliminating primary tumors and distant metastases, the modern trend of **combining radiotherapy with chemotherapy** for Stage IVB patients has shown a promising ability to extend survival and improve palliative outcomes.[14].

Current Treatment Methods For Cervical Cancer

Surgical Interventions

Surgery remains a cornerstone and plays a pivotal role in the definitive management of cervical cancer, particularly for patients diagnosed with **early-stage (FIGO Stage I) disease**. The goal of surgical intervention is not only the complete extirpation of the primary tumor but also the precise pathological staging of the malignancy.

The primary surgical standard is the **radical hysterectomy** (e.g., the Wertheim-Meigs procedure). Unlike a simple hysterectomy, this complex operation involves the en bloc removal of the uterus and cervix along with the surrounding **parametrial tissue** and the upper portion of the vaginal vault. This extensive resection is necessary to ensure clear surgical margins.

In conjunction with the hysterectomy, a **pelvic lymphadenectomy** is typically performed. Removing and analyzing lymph nodes in the pelvic basin is critical to assessing the microscopic extent of metastatic spread. In contemporary practice, **Sentinel Lymph Node (SLN) mapping** is increasingly utilized as a sophisticated, less morbid alternative to full lymphadenectomy, helping to identify the specific nodes most likely to harbor cancer cells while reducing the risk of postoperative lymphedema.

Fertility-Preserving Alternatives

For younger patients who wish to preserve their reproductive potential, the surgical strategy can be adapted depending on the tumor's size and depth of invasion:

- **Cone Biopsy (Conization):** For very small, micro-invasive lesions, removing a cone-shaped wedge of the cervix may be sufficient.
- **Radical Trachelectomy:** This advanced procedure involves removing the cervix and parametrium but **sparing the uterine body**, allowing the patient the possibility of carrying a future pregnancy.

Multimodal Integration and Risks

Surgery is rarely an isolated event in the treatment continuum; it is often strategically integrated with **adjuvant radiation therapy or chemotherapy**. This combination is particularly vital in cases where "high-risk" features—such as positive margins or lympho-vascular space invasion (LVSI)—are discovered during pathological review.

While surgery offers a high potential for a complete cure in

Copy right © Hari Prasad Sonwani

localized cases, it is a significant physiological undertaking. It carries inherent risks and potential complications, including:

- **Acute risks:** Postoperative infection, hemorrhage, and thromboembolism.
- **Structural risks:** Potential iatrogenic damage to the ureters, bladder, or bowel.
- **Long-term impacts:** Possible bladder dysfunction or changes in sexual health.

Consequently, **meticulous patient selection**, supported by high-resolution preoperative imaging and a comprehensive geriatric or nutritional assessment, is essential. When performed by a skilled gynecologic oncologist within a specialized center, surgery remains an indispensable and life-saving component of the cervical cancer treatment paradigm, offering patients the best chance for long-term survival and a return to a high quality of life Surgery stands as a foundational and highly effective intervention in the oncological arsenal against localized malignancies. By facilitating the **direct physical extirpation** of neoplastic tissue, it provides both therapeutic relief and essential diagnostic data. Beyond primary tumor resection, surgical techniques are also strategically employed to debulk or remove **metastatic deposits**, thereby reducing the overall tumor burden on the patient.[14]

For patients diagnosed with **early-stage cervical cancer**, radical surgery remains the definitive gold standard. Historically, this has necessitated a **Type III open radical hysterectomy** coupled with a comprehensive **bilateral pelvic lymph node dissection**. While this extensive procedure is highly effective at ensuring local control, it is often associated with a spectrum of acute and chronic complications, ranging from urinary dysfunction to lymphedema.[15]

Fertility Preservation and Conservative Strategies

In modern gynecologic oncology, a more **conservative surgical philosophy** is applied to women of childbearing age who wish to maintain their reproductive potential. Depending on the specific tumor volume and depth of invasion, several fertility-sparing options are available:

- **Conization and LEEP:** The **Loop Electrosurgical Excision Procedure (LEEP)** and cold-knife conization are utilized for micro-invasive, very low-stage lesions.[16]
- **Radical Trachelectomy:** This involves the removal of the cervix while leaving the uterine fundus intact to support future pregnancy.

It is important to note that while these less-radical procedures show promise for patients with highly favorable prognostic factors, they remain under rigorous clinical evaluation and must be approached with caution to ensure oncological safety remains the priority.

The Shift from Minimally Invasive Surgery (MIS)

Perhaps the most significant recent shift in surgical oncology concerns the method of access. **Minimally Invasive Surgery (MIS)**, including laparoscopic and robotic-assisted techniques, was previously heralded as the standard of care due to faster recovery times. However, landmark longitudinal studies—most notably the **LACC trial**—revealed **poorer survival outcomes** and higher recurrence rates in the MIS group compared to traditional open surgery.[17] This critical evidence has led to a global paradigm shift, reinstating **open abdominal surgery** as the preferred and safer standard for radical hysterectomy in cervical cancer.

Surgical Impact on Advanced Disease

The benefits of surgical intervention extend even into the management of **Stage IVB cervical cancer**. Evidence suggests that integrating surgery with systemic **chemoradiotherapy** can significantly extend life expectancy; patients receiving this multimodal combination achieved a **median survival of 32 months**, compared to only 19 months for those managed without surgical intervention.[14] Beyond increasing longevity, this approach serves a vital palliative function—effectively alleviating distressing symptoms such as chronic pelvic pain and uncontrolled hemorrhage, thereby substantially enhancing the patient's remaining **quality of life**.

Radiotherapy

Radiotherapy serves as a cornerstone and primary treatment modality for cervical cancer, functioning as a definitive curative intervention or a powerful adjuvant following surgical resection. This therapeutic approach utilizes precisely calibrated, **high-energy ionizing radiation beams** designed to induce DNA damage within malignant cells, thereby inhibiting their ability to proliferate while striving to preserve the integrity of adjacent healthy anatomical structures.

The delivery of radiotherapy is categorized into two fundamental methodologies based on the source of the radiation:

1. **External Beam Radiation Therapy (EBRT):** Where the radiation source is located outside the body.
2. **Brachytherapy:** Where a radioactive source is placed internally, either within or in close proximity to the tumor.

Technological Evolution: EBRT and IMRT

The landscape of radiation oncology has been revolutionized by high-energy beam delivery systems. **External Beam Radiation Therapy (EBRT)** remains the most frequently utilized form of radiotherapy, directing potent beams from a linear accelerator into the pelvic region to encompass both the primary tumor and at-risk lymph nodes.

However, the advent of **Intensity-Modulated Radiation Therapy (IMRT)** represents a significant leap in precision. Unlike conventional beams, IMRT utilizes sophisticated computer algorithms to modulate the intensity of individual radiation beams, which may consist of photons or protons. This allows the radiation dose to conform more accurately to the three-dimensional "map" of the tumor, effectively "painting" the cancer with high doses while drastically reducing the exposure of the bladder, rectum, and small bowel.[1,17,18]Modern diagnostic integration, utilizing high-resolution **CT and MRI scans**, has further enhanced this process by providing crystal-clear visualization of malignant invasion and metastatic spread, facilitating highly efficient and personalized radiation planning.

Brachytherapy: The Internal "Boost"

Complementing external treatment is **Brachytherapy (Internal Radiation Therapy)**. By implanting a radioactive device—such as an applicator or specialized needles—directly into the cervical tissue, clinicians can deliver an extremely high, concentrated dose of radiation to the tumor core. This "inside-out" approach is vital because it offers an unparalleled dose-drop-off, meaning the radiation intensity diminishes rapidly as it moves away from the source, thereby sparing the surrounding healthy pelvic tissues from

Copy right © Hari Prasad Sonwani

unnecessary damage.[19]

Challenges, Side Effects, and Combined Modalities

Despite these technological advancements, radiotherapy is not without significant physiological costs. The proximity of the cervix to the gastrointestinal and urinary tracts often leads to common side effects, including:

- **Acute Effects:** Persistent fatigue, skin desquamation, diarrhea, and abdominal cramping.
- **Chronic Sequelae:** Pelvic pain, lymphedema (swelling of the legs), and permanent sexual dysfunction due to vaginal stenosis.[20]

Furthermore, data suggests that **radiotherapy alone fails to achieve local control** in approximately **20% to 50% of cases**, particularly in bulky or advanced tumors.[21,22] To address this limitation and overcome cellular resistance, radiotherapy is now standardly combined with **platinum-based chemotherapy**. This "chemoradiation" strategy acts as a radiosensitizer, making the cancer cells more vulnerable to the lethal effects of the radiation, thereby significantly improving overall survival rates in patients with locally advanced disease.[23].

Chemotherapy

Chemotherapy remains a cornerstone in the comprehensive management of cervical cancer, functioning as a systemic weapon to eradicate circulating cancer cells or arrest their proliferation. This therapeutic modality involves the administration of cytotoxic drugs that disrupt the DNA replication and division cycles of malignant cells. Depending on the disease stage and clinical objectives, chemotherapy may be utilized as a primary intervention, a radiosensitizer, or as an adjuvant therapy following surgical resection.

While the systemic nature of these drugs often impacts healthy tissues—leading to transient side effects—chemotherapy is indispensable for patients with advanced, recurrent, or metastatic disease. Modern research continues to evolve toward more refined, targeted, and less toxic regimens designed to enhance survival while safeguarding the patient's quality of life.

Therapeutic Strategies and Agent Selection

The clinical application of chemotherapy is highly versatile. It is standardly integrated with radiotherapy (chemoradiation) following surgery or used as a standalone monotherapy for locally advanced cases where surgical intervention is not feasible. Depending on a patient's performance status and the molecular profile of the tumor, treatment may involve:

- **Monotherapy:** Typically using a single potent agent like cisplatin.
- **Combination (Dual or Triple) Therapy:** Integrating multiple drugs to target different cellular pathways.[5]

A wide array of pharmacological agents has demonstrated activity against cervical cancer, including platinum-based drugs (cisplatin, carboplatin), gemcitabine, topotecan, taxanes (paclitaxel), vinorelbine, and ifosfamide. Additionally, the targeted monoclonal antibody **bevacizumab** is frequently integrated into these regimens to inhibit tumor angiogenesis.[24]

The Role of Cisplatin and Overcoming Resistance

Despite the variety of available options, **cisplatin** has historically been identified as the most effective single agent for treating cervical cancer.[25] When administered at a standard dose of every three weeks, cisplatin has achieved objective response rates of up to **38%**.[26] Its mechanism of action involves creating intra-strand DNA adducts that trigger programmed cell death (apoptosis). However, a significant clinical challenge is that many tumors—while initially responsive—eventually develop **acquired resistance**, rendering the treatment less effective over time.[16]

Synergistic Combinations for Enhanced Efficacy

To combat resistance and boost therapeutic potency, recent protocols favor combining cisplatin with other cytotoxic agents. Clinical evidence suggests that multi-drug regimens offer a higher potential for success than monotherapy. For instance:

- **Cisplatin + Paclitaxel:** A landmark study by **DH Moore et al.** revealed that while cisplatin alone yielded a **19%** response rate, the addition of paclitaxel nearly doubled the efficacy to **36%**.[27]
- **Cisplatin + Topotecan:** Similarly, trials combining topotecan (a topoisomerase I inhibitor) with cisplatin have demonstrated significant improvements in both progression-free and overall survival for patients with advanced or recurrent disease.[28]

In summary, chemotherapy is an essential pillar of cervical cancer care. While cisplatin remains the traditional "backbone" of treatment, the transition toward combination regimens—pairing it with agents like paclitaxel or topotecan—has redefined the standard of care by significantly enhancing clinical response rates and long-term outcomes.

Immunotherapy

Immunotherapy represents a transformative shift in cervical cancer management, moving away from direct cytotoxicity toward harnessing the patient's own **immune surveillance** to identify and eradicate malignant cells. This sophisticated approach centers on **immune checkpoint inhibitors (ICIs)**, which are engineered to block specific proteins that act as "molecular brakes," preventing the immune system from attacking cancer cells. Specifically, the inhibition of **programmed cell death protein 1 (PD-1)** and its ligands (**PD-L1 and PD-L2**) has demonstrated remarkable clinical efficacy. By disrupting these interactions, ICIs reactivate suppressed T cells, enabling them to recognize and neutralize tumors more effectively. This modality has become an essential lifeline, particularly for patients who have exhausted traditional surgical or chemotherapeutic options.

Historically, therapeutic alternatives were exceedingly limited for patients who progressed following first-line platinum-based therapy. However, the integration of ICIs, including those targeting **cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)**, has marked a significant breakthrough in contemporary oncology.[29,30]

Landmark Trials and Evolving Standards (2024–2025)

The clinical journey of immunotherapy in this field began with the **Phase Ib KEYNOTE-028** trial, which provided the foundational evidence for **pembrolizumab** (an anti-PD-1 monoclonal antibody). This study reported a **17% overall response rate (ORR)** in advanced cases, with a safety profile consistent with its use in other malignancies.[31] Building upon this, the **CheckMate-358** trial explored combination strategies, pairing nivolumab (PD-1 inhibitor) with ipilimumab (CTLA-4 inhibitor).

Copy right © Hari Prasad Sonwani

The results revealed optimal response rates in recurrent/metastatic squamous cervical cancer, with the greatest efficacy observed in treatment-naïve populations.[32]

By **2025**, the landscape has advanced even further with the results of the **KEYNOTE-A18** (ENGOT-cx11) trial. This landmark study established a new standard of care by integrating pembrolizumab with **concurrent chemoradiotherapy (CRT)** for newly diagnosed, high-risk, locally advanced cervical cancer. Final descriptive analyses presented in 2025 confirmed a **33% reduction in the risk of death** (HR: 0.67$), solidifying immunotherapy's role in the frontline setting rather than just as a second-line "rescue" therapy.

Emerging Bispecific Antibodies and Novel Agents

Innovation continues with the development of **bispecific monoclonal antibodies**, which target two distinct pathways simultaneously. **Cadonilimab**, a novel anti-PD-1/CTLA-4 bispecific agent, has shown exceptional promise as a monotherapy for patients who failed prior platinum-based regimens. In pivotal trials, cadonilimab achieved an **Overall Response Rate (ORR) of 33%**, which surged to **43.8%** in patients with PD-L1-positive tumors.[33]

Furthermore, the recent regular approval of **Tisotumab vedotin** (an antibody-drug conjugate) and ongoing research into **HPV-targeted vaccines** and **CAR-T cell therapies** signify a future where immunotherapy is not just an alternative, but a cornerstone of personalized, biomarker-driven care. While immune-related adverse events (irAEs)—such as hypothyroidism or colitis—require vigilant monitoring, the manageable safety profile of these agents continues to improve patient survival and long-term prognosis.

Targeted Therapy

Targeted therapy for cervical cancer represents a paradigm shift toward precision oncology, utilizing pharmacological agents designed to interfere with specific molecular pathways essential for tumor growth, angiogenesis, and survival. Unlike conventional cytotoxic chemotherapy, which broadly impacts rapidly dividing cells, these therapies aim to inhibit malignant proliferation while significantly sparing healthy tissues. The most prominent strategies involve blocking the **Epidermal Growth Factor Receptor (EGFR)** and the **Vascular Endothelial Growth Factor (VEGF)**, both of which have demonstrated substantial clinical efficacy in late-stage and refractory cases when integrated with standard treatment regimens.

By focusing on proteins uniquely expressed or overexpressed by cancer cells, targeted therapies offer a more precise and generally less toxic therapeutic window than traditional systemic treatments.[16]

Angiogenesis Inhibition: The Role of Bevacizumab

A landmark advancement in this field was the **Phase III GOG 240** trial, which rigorously evaluated the integration of **bevacizumab**—a monoclonal antibody that neutralizes VEGF—into non-platinum and platinum-based chemotherapy doublets for patients with advanced cervical cancer. The trial results were transformative:

- **Survival Benefit:** The addition of bevacizumab increased the median overall survival from **13.3 months to 17.0 months** (and as high as **16.8 months** in specific pooled analyses).[34]
- **Response Rates:** Patients receiving the triplet therapy achieved significantly higher objective response rates (**48%**) compared to those receiving chemotherapy alone (**36%**).[34]

Currently, the combination of **cisplatin, paclitaxel, and bevacizumab** is considered the international standard of care for persistent, recurrent, or metastatic cervical cancer. However, clinicians must remain vigilant regarding bevacizumab-specific toxicities, including hypertension, thromboembolic events, and the risk of gastrointestinal or vaginal fistulas.[34]

2025 Advancements: Antibody-Drug Conjugates (ADCs)

Moving into 2025, the targeted therapy landscape has expanded to include **Antibody-Drug Conjugates (ADCs)**, which act as "molecular trojan horses." A prime example is **Tisotumab vedotin (Tivdak)**, which targets **Tissue Factor (TF)**—a protein highly expressed on the surface of cervical cancer cells. In the pivotal **innovaTV 301** trial (2024–2025), tisotumab vedotin demonstrated a **30% reduction in the risk of death** compared to standard second-line chemotherapy. This breakthrough has introduced a new mechanism of action for patients who have progressed on prior bevacizumab and platinum-based therapies, offering a critical third-line option. Additionally, emerging trials are investigating **HER2-directed ADCs** (such as Trastuzumab deruxtecan) for the small percentage of cervical cancer patients with HER2-positive expression, further personalizing the treatment journey.

Future Prospects In Cervical Cancer Management

Therapeutic Vaccines: Reversing Infection and Malignancy

While prophylactic vaccines are highly successful in generating humoral immunity to prevent new infections, they offer no therapeutic benefit for individuals already harboring high-risk HPV strains. Consequently, **HPV therapeutic vaccines** have emerged as a cutting-edge area of research. These are classified into several innovative platforms: **live vector-based vaccines**, **peptide and protein-based vaccines**, **nucleic acid (DNA/mRNA) vaccines**, and **whole-cell vaccines**.[35]

The primary mechanism of these vaccines involves targeting the **HPV E6 and E7 oncoproteins**. These proteins are constitutively expressed in HPV-infected cells and act as the fundamental drivers of malignant transformation by inactivating tumor suppressor proteins like p53 and pRb. The overarching goal is to stimulate a robust **CD8+ cytotoxic T-cell response** capable of recognizing these oncoproteins, thereby selectively eliminating infected cells and halting the progression from pre-neoplasia to invasive cancer.[35]

Advances in Clinical Efficacy (2024–2025)

Significant progress has been made with specific vaccine candidates:

- **MVA-E2:** This modified vaccinia Ankara-based vaccine remains a top-performing candidate. Early studies demonstrated a **90% regression rate** in high-grade cervical precancerous lesions, mimicking the success of conventional surgical interventions. However, researchers have noted that the absence of a control group in initial trials makes it difficult to distinguish vaccine-induced regression from natural viral clearance.[36]
- **Vvax001:** In late 2024 and early 2025, the **Vvax001** (a viral vector vaccine) showed promising Phase II results, achieving a **histopathologic complete response in 50%** of

Copy right © Hari Prasad Sonwani

patients with CIN3. This could eventually provide a non-surgical alternative for women, preserving cervical integrity and reproductive health.[4.4]

- **Nasal Vaccines:** Innovative research in 2025 has introduced **intranasal therapeutic vaccines** using nanogel delivery systems. These are designed to trigger a localized mucosal immune response directly in the reproductive tract, offering a needle-free and highly targeted approach to treating existing infections.{1.4}

Synergistic Combination Therapies

The most potent future strategy involves **combination therapy**, pairing therapeutic vaccines with **immunotherapy (ICIs)** to overcome the immunosuppressive tumor microenvironment.

- **ISA101 and Nivolumab:** A notable example is the **ISA101** peptide vaccine. When combined with the PD-1 inhibitor **nivolumab**, it achieved a **33% objective response rate** in a Phase II study for HPV16-positive cancers.[37] While initial results in advanced, heavily pre-treated cervical cancer patients were less consistent, long-term follow-up data in 2025 suggests that patients with high "immune infiltration" scores benefit significantly from this duo.

Ongoing research now focuses on optimizing vaccine antigens and identifying **biomarkers** (such as PD-L1 status or T-cell density) to ensure these adjuvants prevent invasive procedures and reduce the high rate of recurrence observed in advanced disease.[35,36].

PARP Inhibitors

Poly (Adenosine Diphosphate [ADP]-ribose) polymerase, particularly the **PARP1** isoform, is a vital nuclear enzyme that serves as a molecular sensor and facilitator for the repair of single-strand DNA breaks (SSBs). PARP inhibitors (PARPi), such as **olaparib** and **veliparib**, function by trapping the PARP enzyme on damaged DNA sites and preventing the recruitment of repair proteins. This inhibition is exceptionally lethal to malignant cells that already harbor defects in the **homologous recombination (HR)** repair pathway—a concept known as **synthetic lethality**. When PARPi-induced DNA damage cannot be resolved by the cell's backup repair mechanisms, the resulting accumulation of double-strand breaks triggers programmed cell death (apoptosis)[37].

While traditionally utilized in ovarian and breast cancers, PARP inhibitors are emerging as a promising targeted strategy for specific subsets of cervical cancer. A notable case report by **Gross M and Spencer RJ** highlighted the potential of single-agent olaparib, which induced a dramatic clinical response in a patient with recurrent metastatic clear cell cervical cancer, maintaining disease stability for over **14 months** without progression.[38]

Clinical Efficacy and Combination Strategies

In the broader context of cervical cancer management, researchers are shifting away from monotherapy toward synergistic combinations to enhance therapeutic impact:

- **Combination with Chemotherapy:** A pivotal clinical trial evaluating the integration of **veliparib** with a paclitaxel and cisplatin doublet achieved a significant **34% objective response rate** and a median overall survival of **14.5 months** in patients with advanced disease.[39]
- **The Role of Biomarkers:** By **2025**, the focus has intensified on identifying **Homologous Recombination Deficiency (HRD)** or "BRCAness" in cervical tumors. Although BRCA mutations are less common in cervical cancer than in ovarian cancer, emerging evidence suggests that HPV-mediated epigenetic changes can occasionally mimic an HRD phenotype, potentially expanding the patient population eligible for PARP inhibition.
- **Radiosensitization:** PARP inhibitors are also being investigated as potent **radiosensitizers**. By blocking the repair of radiation-induced DNA damage, agents like veliparib may significantly increase the efficacy of standard external beam radiation therapy, particularly in bulky or radioresistant tumors.

Future Directions and Safety

Despite these promising signals, further large-scale Phase III clinical trials are mandatory to definitively establish the clinical effectiveness and optimal sequencing of PARP inhibitors in cervical cancer. Safety profiles must be carefully monitored, as the combination of PARPi with cytotoxic chemotherapy can exacerbate **hematological toxicities**, such as anemia and neutropenia. As we move further into 2025, the integration of PARP inhibitors with immunotherapy (the "triple threat" approach—PARPi, anti-angiogenics, and ICIs) remains a highly anticipated frontier in the pursuit of personalized, high-efficacy treatment for recurrent cervical malignancies.

Antibody-Drug Conjugates (ADCs)

Tisotumab vedotin (Tivdak) represents a breakthrough in precision oncology as a first-in-class **antibody-drug conjugate (ADC)**. Its structural design functions as a "molecular trojan horse," combining a high-affinity human monoclonal antibody with a potent cytotoxic payload.

Mechanism of Action

The therapeutic efficacy of tisotumab vedotin is derived from its three-component structure:

1. **The Antibody:** A fully human IgG1 monoclonal antibody that specifically targets **Tissue Factor (TF)**. This transmembrane protein is overexpressed in nearly 94–100% of cervical cancer cells but has limited expression in healthy tissues, providing a clear target for the drug.
2. **The Payload: Monomethyl auristatin E (MMAE)**, a potent anti-microtubular agent that is too toxic to be administered as a standard systemic chemotherapy.
3. **The Linker:** A protease-cleavable valine-citrulline linker that ensures the payload remains securely attached while in the bloodstream but is rapidly released once inside the tumor cell.

Upon binding to the Tissue Factor on the cancer cell surface, the entire ADC-TF complex is internalized via endocytosis. Once inside the lysosome, cellular enzymes cleave the linker, releasing the MMAE. This agent then **disrupts the microtubule network** essential for cell division, leading to G2/M cell cycle arrest and subsequent apoptotic cell death.

Copy right © Hari Prasad Sonwani

Clinical Milestones and 2024–2025 Evolution

Initially receiving accelerated approval in September 2021,[40] tisotumab vedotin has since solidified its role in the global therapeutic landscape:

- **Traditional FDA Approval (April 2024):** Based on the successful results of the **Phase III innovaTV 301** trial, the FDA granted full traditional approval. The trial demonstrated a **30% reduction in the risk of death** compared to investigator-choice chemotherapy, with a median overall survival of 11.5 months.
- **NCCN Guidelines (2025):** As of 2025, it is recognized as the **only Category 1 preferred option** for second-line or subsequent therapy for recurrent or metastatic cervical cancer.
- **Global Expansion:** In 2025, it received marketing authorization from the **European Commission** and the Japanese Ministry of Health, Labour, and Welfare, making it the first ADC approved for this indication in these regions.

While highly effective, the drug is associated with specific "side effects of interest," including **ocular toxicities** (conjunctivitis and corneal ulcers) and peripheral neuropathy, necessitating strict adherence to eye-care premedication and monitoring protocols.

Ribonucleotide Reductase (RR) Inhibitors

Ribonucleotide Reductase (RR) serves as a rate-limiting enzyme essential for DNA synthesis and cellular repair mechanisms. It facilitates the biochemical reduction of nucleoside diphosphates into their corresponding deoxynucleotides (dNTPs), which are the fundamental building blocks of DNA. In cervical cancer, high-risk HPV oncoproteins (E6 and E7) often lead to an overactivation of RR, allowing malignant cells to rapidly repair DNA damage and survive aggressive treatment.[41]Consequently, RR inhibitors such as **hydroxyurea** and **triapine** have been investigated as potent radiosensitizers that can starve the tumor of the resources needed for recovery.

Hydroxyurea: The Traditional Sensitizer

The landmark **GOG 120** trial demonstrated that radiation therapy combined with either cisplatin alone or a "triple-threat" combination of cisplatin, fluorouracil, and hydroxyurea was highly effective for locally advanced cervical cancer.[42] By blocking DNA synthesis during the S-phase of the cell cycle, hydroxyurea ensures that cancer cells remain in a vulnerable state, unable to fix the double-strand breaks caused by ionizing radiation. While it has been a staple in historical protocols, its use has somewhat shifted as newer, more specific agents emerge.

Triapine: The Next-Generation Inhibitor

Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is a significantly more potent RR inhibitor than hydroxyurea. It works by sequestering the iron required for the enzyme's catalytic subunit, effectively "shutting down" the production of DNA precursors. Early-phase clinical trials and animal models have suggested that triapine drastically sensitizes tumors to radiation, specifically in cervical and vaginal malignancies.[43]

Recent updates in **2024–2025** have highlighted further progress:

- **Enhanced Complete Response Rates:** Phase II trial data indicated that adding triapine to standard cisplatin-chemoradiation resulted in a **metabolic complete response rate of up to 95%** in advanced cases, compared to roughly 70–75% with standard therapy alone.
- **Ongoing Phase III Validation:** To solidify these findings, the **NRG-GY006 (NCT02466971)** trial—a randomized Phase III study—is currently finalizing data to compare standard chemoradiation against the triapine-supplemented regimen.
- **Mechanism of Synergy:** Research in 2025 has confirmed that triapine's 2-hour half-life allows for precise "pulse" dosing that maximizes tumor DNA damage while minimizing long-term toxicity to normal pelvic tissues.

While triapine shows immense promise in "resetting" the sensitivity of resistant tumors, further large-scale confirmation is necessary before it can be formally integrated into universal clinical guidelines for all stages of cervical cancer.

Ongoing Clinical Trials

Ongoing clinical trials in cervical cancer are fundamentally reshaping the future of treatment paradigms with groundbreaking new approaches. Trials like **INTERLACE** and **KEYNOTE-A18** are at the absolute forefront, investigating the clinical impact of induction chemotherapy and immune checkpoint inhibitors on treatment outcomes for locally advanced cervical cancer.

The **INTERLACE** trial has recently redefined the standard of care by demonstrating that a short six-week course of induction chemotherapy (carboplatin and paclitaxel) prior to standard chemoradiotherapy significantly boosts survival. Results published in **2024–2025** revealed a **40% reduction in the risk of death** and a **35% reduction in cancer recurrence**, marking the most substantial survival improvement for locally advanced disease in over two decades.[44]Similarly, the **KEYNOTE-A18** (ENGOT-cx11) trial has highlighted the transformative potential of combining **pembrolizumab** with traditional chemoradiotherapy. Updated 2025 data confirmed that this regimen reduces the risk of death by **33%**, establishing it as a new first-line standard for high-risk patients.[44]

In the setting of advanced, recurrent, or metastatic cervical cancer, trials such as **KEYNOTE-826** and **BEATcc** are exploring the synergistic effects of combining immune checkpoint inhibitors with chemotherapy and anti-angiogenic agents. The **BEATcc** trial specifically demonstrated that adding **atezolizumab** to the standard cisplatin-paclitaxel-bevacizumab triplet significantly extends overall survival, reaching a median of **32.1 months**.^{44} Furthermore, the global approval of **tisotumab vedotin** (Tivdak) for second-line treatment marks a significant leap in precision medicine. This antibody-drug conjugate (ADC), which targets Tissue Factor, is currently being evaluated in various combinations to determine its efficacy as an earlier line of defense.[45]

Several other specific trials provide critical insights into management:

- **XmAb20717 (Vudalimab):** This Phase 2 trial is evaluating the efficacy of a novel **bispecific antibody** that simultaneously targets PD-1 and CTLA-4. While the study was suspended briefly for protocol refinements in 2024, it remains a

Copy right © Hari Prasad Sonwani

key area of interest for patients with advanced gynecologic malignancies who are refractory to standard ICIs.^{46}

- **The ROCC Trial (GOG-3043):** This landmark randomized controlled trial iscomparing survival outcomes between **robotic-assisted laparoscopic surgery** and traditional open radical hysterectomy. Following the LACC trial's findings that favored open surgery, the ROCC trial aims to determine if modern robotic assistance—using strict tumor-containment techniques—can offer non-inferior oncological outcomes with the benefits of minimally invasive recovery.[46]
- **The ACCESS Trial:** This implementation-focused study is integrating cervical cancer "screen-and-treat" services within existing **HIV care programs** in Nigeria. By exploring various delivery strategies, the trial aims to improve health equity for underserved populations.[46] The ACCESS model's focus on integrating care could serve as a vital blueprint for countries like **India**, where the dual burden of HIV and cervical cancer is significant. Such an approach could streamline healthcare services, improve cost-effectiveness, and ultimately enhance the life expectancy of women facing these co-occurring health challenges.

Conclusion

In summary, cervical cancer remains a formidable global health challenge, yet the therapeutic landscape has reached a pivotal "tipping point" in 2025. While conventional treatments—surgery, radiotherapy, and cisplatin-based chemotherapy—have formed the bedrock of care for decades, their limitations in advanced and recurrent settings are now being addressed by a surge of innovative alternatives. The integration of **precision medicine, immunotherapy, and targeted biologics** into standard clinical protocols is no longer a future prospect but a current reality that is actively improving patient survival and quality of life.

The transition toward **biomarker-driven therapy**—where treatment is tailored to a tumor's specific molecular signature, such as PD-L1 expression or HPV oncoprotein activity—represents the most significant shift in modern gynecologic oncology. Breakthroughs in **Antibody-Drug Conjugates (ADCs)** like tisotumab vedotin and the successful implementation of **induction chemotherapy** (as seen in the INTERLACE trial) offer new hope for high-risk and refractory cases. Furthermore, the advent of **therapeutic vaccines** and **CRISPR-based gene editing** provides a visionary path toward not just treating, but potentially reversing, the cellular damage caused by persistent high-risk HPV infections. Ultimately, the future of cervical cancer management lies in the synergy of **prevention and precision**. To realize a "cervical cancer-free world," we must align these medical advancements with the **World Health Organization's 2030 targets**:

- **90%** HPV vaccination coverage.
- **70%** screening with high-performance tests.
- **90%** access to high-quality treatment.

Continued collaborative efforts between clinicians, researchers, and global health organizations are essential to optimize these regimens and ensure that life-saving innovations are accessible to all women, regardless of socioeconomic status. By bridging the gap between bench-side research and bedside care, we can move closer to the ultimate goal of eliminating cervical cancer as a public health threat within this century.

funding: not applicable.

conflict of interest: the authors declare that there is no conflict of interest.

ethical approval: not applicable.

Author contribution: Hari Sonwani: Formal analysis, Visualization, Writing – review & editing.

References:

1. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. *The Lancet*. 2019;393(10167):169-82. doi: 10.1016/S0140-6736(18)32470-X
2. Torres-Poveda K, Cruz-Valdez A, Madrid-Marina V. Epidemiología del cáncer cervicouterino. *Gac Mex Oncol*. 2014;13(4):4-17. doi: 10.1016/j.gamo.2014.07.001
3. Moodley JR, Hoffman M, Carrara H, et al. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. *BMC Cancer*. 2006;6:129. doi: 10.1186/1471-2407-6-129
4. Salvo G, Odetto D, Pareja R, et al. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: a review of gaps and questions that remain. *Int J Gynecol Cancer*. 2020;30(6):873-878. doi: 10.1136/ijgc-2020-001257
5. Porras GOR, Nogueda JC, Chacón AP. Chemotherapy and molecular therapy in cervical cancer. *Rep Pract Oncol Radiother*. 2018;23(6):533-9. doi: 10.1016/j.rpor.2018.06.002
6. Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2017;28:iv72-83. doi: 10.1093/annonc/mdx220
7. Greimel E, Lahousen M, Dorfer M, et al. Patients' view of routine follow-up after gynecological cancer treatment. *Eur J Obstet Gynecol Reprod Biol*. 2011;159(1):180-3. doi: 10.1016/j.ejogrb.2011.07.020
8. DeVita VT, Lawrence TS, Rosenberg SA. *DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology*. Vol. 2. Lippincott Williams & Wilkins; 2008. doi: 10.1097/01.COT.0000344585.55831.06
9. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix... *J Clin Oncol*. 1999;17(5):1339. doi: 10.1200/JCO.1999.17.5.1339
10. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. *N Engl J Med*. 1999;340(15):1137-43. doi: 10.1056/NEJM199904153401501
11. Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea... *J Clin Oncol*. 2007;25(19):2804-10. doi:

Copy right © Hari Prasad Sonwani

10.1200/JCO.2006.09.4151
12. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. *The Lancet*. 2001;358(9284):781-6. doi: 10.1016/S0140-6736(01)05965-7
13. Tewari KS, Monk BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer. *N Engl J Med*. 2022;386(6):544-55. doi: 10.1056/NEJMoa2112187
14. Li H, Pang Y, Cheng X. Surgery of primary sites for stage IVB cervical cancer patients receiving chemoradiotherapy: a population-based study. *J Gynecol Oncol*. 2020;31(1):e8. doi: 10.3802/jgo.2020.31.e8
15. Poddar P, Maheshwari A. Surgery for cervical cancer: consensus & controversies. *Indian J Med Res*. 2021;154(2):284-92. doi: 10.4103/ijmr.IJMR_581_21
16. Burmeister CA, Khan SF, Schäfer G, et al. Cervical cancer therapies: Current challenges and future perspectives. *Tumour Virus Res*. 2022;13:200238. doi: 10.1016/j.tvr.2022.200238
17. Cibula D, Pötter R, Planchamp F, et al. The ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer. *Virchows Arch*. 2018;472:919-36. doi: 10.1007/s00428-018-2362-9
18. Johnson CA, James D, Marzan A, Armaos M. Cervical cancer: an overview of pathophysiology and management. *Semin Oncol Nurs*. 2019;35(2):166-74. doi: 10.1016/j.soncn.2019.02.003
19. PDQ® Adult Treatment Editorial Board. Cervical Cancer Treatment (PDQ®): Health Professional Version. 2002. doi: 10.1515/jpm-2019-0144
20. Wang K, Tepper JE. Radiation therapy-associated toxicity: Etiology, management, and prevention. *CA Cancer J Clin*. 2021;71(5):437-54. doi: 10.3322/caac.21689
21. Moreno-Acosta P, Vallard A, Carrillo S, et al. Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinoma. *Radiat Oncol*. 2017;12:120. doi: 10.1186/s13014-017-0857-4
22. Rahakbauw E, Winarto H. Radiotherapy response and related clinicopathological factors of patients with cervical cancer. *J Phys Conf Ser*. 2018;1073:032040. doi: 10.1088/1742-6596/1073/3/032040
23. Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. *Clin Adv Hematol Oncol*. 2010;8(2):108-15. PMID: 20400931 (Note: DOI often unavailable for this specific supplement)
24. Serrano-Olivera J, Cortés-Esteban P, Poitevin-Chacón A. Cáncer cervicouterino: tratamiento de la enfermedad persistente, recurrente o metastásica. *Gac Mex Oncol*. 2014;13(4):75-82. doi: 10.1016/j.gamo.2014.07.011
25. Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. *Curr Oncol Rep*. 2005;7:419-34. doi: 10.1007/s11912-005-0007-z
26. Verma J, Monk BJ, Wolfson AH. New strategies for multimodality therapy in treating locally advanced cervix cancer. *Semin Radiat Oncol*. 2016;26(4):344-8. doi: 10.1016/j.semradonc.2016.06.003
27. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma... *J Clin Oncol*. 2004;22(15):3113-9. doi: 10.1200/JCO.2004.04.170
28. Long III HJ, Bundy BN, Grendys Jr EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix... *J Clin Oncol*. 2005;23(21):4626-33. doi: 10.1200/JCO.2005.10.021
29. Grau-Bejar JF, Garcia-Duran C, Garcia-Illescas D, et al. Advances in immunotherapy for cervical cancer. *Ther Adv Med Oncol*. 2023;15:17588359231163836. doi: 10.1177/17588359231163836
30. Kagabu M, Nagasawa T, Sato C, et al. Immunotherapy for uterine cervical cancer using checkpoint inhibitors: future directions. *Int J Mol Sci*. 2020;21(7):2335. doi: 10.3390/ijms21072335
31. Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: KEYNOTE-028. *J Clin Oncol*. 2017;35(36):4035-41. doi: 10.1200/JCO.2017.74.5448
32. Oaknin A, Moore K, Meyer T, et al. Safety and efficacy of nivolumab ± ipilimumab in patients with recurrent/metastatic cervical cancer in CheckMate 358. *Ann Oncol*. 2022;33:S782. doi: 10.1016/j.annonc.2022.07.649
33. Wu X, Ji J, Lou H, et al. Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic cervical cancer. *Gynecol Oncol*. 2022;166:S47-8. doi: 10.1016/j.ygyno.2022.05.143
34. Tewari KS, Sill MW, Long III HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med*. 2014;370(8):734-43. doi: 10.1056/NEJMoa1309748
35. Mo Y, Ma J, Zhang H, et al. Prophylactic and therapeutic HPV vaccines: current scenario and perspectives. *Front Cell Infect Microbiol*. 2022;12:909223. doi: 10.3389/fcimb.2022.909223
36. Khalil AI, Zhang L, Muwonge R, et al. Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis. *BMJ Open*. 2023;13(10):e069616. doi: 10.1136/bmjopen-2022-069616
37. Rumfield CS, Pellom ST, Morillon II YM, et al. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. *J Immunother Cancer*. 2020;8(1):e000473. doi: 10.1136/jitc-2019-000473
38. Gross M, Spencer RJ. Recurrent cervical cancer treated successfully with single-agent PARP-inhibitor, olaparib. *Case Rep Obstet Gynecol*. 2022;2022:8392131. doi: 10.1155/2022/8392131
39. Thaker P, Salani R, Brady W, et al. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix... *Ann Oncol*. 2017;28(3):505-11. doi: 10.1093/annonc/mdw661
40. Bogani G, Coleman RL, Vergote I, et al. Tisotumab vedotin in recurrent or metastatic cervical cancer. *Curr Probl Cancer*. 2023;47(3):100952. doi: 10.1016/j.currproblcancer.2023.100952
41. Heidel JD, Liu JYC, Yen Y, et al. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. *Clin Cancer Res*. 2007;13(7):2207-15. doi: 10.1158/1078-0432.CCR-06-2124
42. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced

Copy right © Hari Prasad Sonwani

cervical cancer. *N Engl J Med*. 1999;340(15):1144-53. doi: 10.1056/NEJM199904153401502

43. Chapman TR, Kinsella TJ. Ribonucleotide reductase inhibitors: a new look at an old target for radio sensitization. *Front Oncol*. 2012;1:56. doi: 10.3389/fonc.2011.00056
44. Ang DJ, Chan JJ. Evolving standards and future directions for systemic therapies in cervical cancer. *J Gynecol Oncol*. 2024;35(2):e58. doi: 10.3802/jgo.2024.35.e58
45. Monk BJ, Enomoto T, Kast WM, et al. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials. *Cancer Treat Rev*. 2022;106:102385. doi: 10.1016/j.ctrv.2022.102385
46. UCSD. UCSD Cervical Cancer Clinical Trials-San Diego [Internet]. clinicaltrials.ucsd. edu. Available from: https://clinicaltrials.ucsd.edu/cervical-cancer.

Copy right © Hari Prasad Sonwani